FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4328003547> ?p ?o ?g. }

• W4328003547 endingPage "706" @default.
• W4328003547 startingPage "689" @default.
• W4328003547 abstract "As one of the most common causes of death in advanced non-small cell lung cancer (NSCLC), brain metastases (BM) have attracted attention and debate about treatment options, especially for patients with negative driver genes or resistance to targeted agents. Therefore, we conducted a meta-analysis to investigate the potential benefit of different therapeutic regimens for intracranial lesions in non-targeted therapy NSCLC patients.A comprehensive search was conducted in databases including PubMed, Embase, and the Cochrane Library. The primary endpoints included the intracerebral objective response rate (icORR) and intracerebral progression-free survival (iPFS) in patients with BM.Thirty-six studies involving 1,774 NSCLC patients with baseline BM were included in this meta-analysis. Antitumor agents plus radiotherapy (RT) showed the most significant synergistic effects; the highest pooled icORR that appeared in the combination of immune checkpoint inhibitor (ICI) and RT was 81% [95% confidence interval (CI): 16-100%], and the median iPFS was 7.04 months (95% CI: 2.54-11.55 months). The pooled icORR and median iPFS of RT plus chemotherapy were 46% (95% CI: 34-57%) and 5.7 months (95% CI: 3.90-7.50 months), respectively. The highest median iPFS in nivolumab plus ipilimumab plus chemotherapy was 13.5 months (95% CI: 8.35-18.65 months). ICI plus chemotherapy also showed potent antitumor activity in BM, with a pooled icORR of 56% (95% CI: 29-82%) and a median iPFS of 6.9 months (95% CI: 3.20-10.60 months). Notably, the subgroup analysis indicated that the pooled icORR of patients in programmed cell death-ligand 1 (PD-L1) (≥50%) who received ICI was 54% (95% CI: 30-77%), and that of patients who received first-line ICI was 69.0% (95% CI: 51-85%).ICI-based combination treatment provides a long-term survival benefit for non-targeted therapy patients, with the most significant benefits observed in improving icORR and prolonging overall survival (OS) and iPFS. In particular, patients who received first-line treatment or who were PD-L1-positive had a more significant survival benefit from aggressive ICI-based therapies. For patients with a PD-L1-negative status, chemotherapy plus RT led to better clinical outcomes than other treatment regimens. These innovative findings could help clinicians to better select therapeutic strategies for NSCLC patients with BM." @default.
• W4328003547 created "2023-03-22" @default.
• W4328003547 creator A5006126476 @default.
• W4328003547 creator A5025755637 @default.
• W4328003547 creator A5026262593 @default.
• W4328003547 creator A5043858190 @default.
• W4328003547 creator A5046856172 @default.
• W4328003547 creator A5047686585 @default.
• W4328003547 creator A5065243448 @default.
• W4328003547 creator A5076139079 @default.
• W4328003547 date "2023-04-01" @default.
• W4328003547 modified "2023-09-30" @default.
• W4328003547 title "Efficacy of different therapies for brain metastases of non-small cell lung cancer: a systematic review and meta-analysis" @default.
• W4328003547 cites W1949869328 @default.
• W4328003547 cites W2031824420 @default.
• W4328003547 cites W2036057719 @default.
• W4328003547 cites W2067070784 @default.
• W4328003547 cites W2078763461 @default.
• W4328003547 cites W2089597174 @default.
• W4328003547 cites W2103451990 @default.
• W4328003547 cites W2105067160 @default.
• W4328003547 cites W2136371443 @default.
• W4328003547 cites W2143843774 @default.
• W4328003547 cites W2156098321 @default.
• W4328003547 cites W2158023296 @default.
• W4328003547 cites W2158777895 @default.
• W4328003547 cites W2171136529 @default.
• W4328003547 cites W2237949895 @default.
• W4328003547 cites W2325597619 @default.
• W4328003547 cites W2416906314 @default.
• W4328003547 cites W246286872 @default.
• W4328003547 cites W2618641368 @default.
• W4328003547 cites W2772183668 @default.
• W4328003547 cites W2782652081 @default.
• W4328003547 cites W2808057716 @default.
• W4328003547 cites W2911788634 @default.
• W4328003547 cites W2912571746 @default.
• W4328003547 cites W2915024982 @default.
• W4328003547 cites W2919530208 @default.
• W4328003547 cites W2920978728 @default.
• W4328003547 cites W2956407134 @default.
• W4328003547 cites W2966453812 @default.
• W4328003547 cites W2967398918 @default.
• W4328003547 cites W2990655302 @default.
• W4328003547 cites W3009099064 @default.
• W4328003547 cites W3014209163 @default.
• W4328003547 cites W3043378539 @default.
• W4328003547 cites W3098234339 @default.
• W4328003547 cites W3100581984 @default.
• W4328003547 cites W3107567162 @default.
• W4328003547 cites W3109548846 @default.
• W4328003547 cites W3110062385 @default.
• W4328003547 cites W3112840022 @default.
• W4328003547 cites W3113013797 @default.
• W4328003547 cites W3113942966 @default.
• W4328003547 cites W3135841412 @default.
• W4328003547 cites W3138442964 @default.
• W4328003547 cites W3155565607 @default.
• W4328003547 cites W3159551768 @default.
• W4328003547 cites W3170987234 @default.
• W4328003547 cites W3178873995 @default.
• W4328003547 cites W4280556356 @default.
• W4328003547 cites W4297184088 @default.
• W4328003547 doi "https://doi.org/10.21037/tlcr-22-515" @default.
• W4328003547 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37197616" @default.
• W4328003547 hasPublicationYear "2023" @default.
• W4328003547 type Work @default.
• W4328003547 citedByCount "1" @default.
• W4328003547 countsByYear W43280035472023 @default.
• W4328003547 crossrefType "journal-article" @default.
• W4328003547 hasAuthorship W4328003547A5006126476 @default.
• W4328003547 hasAuthorship W4328003547A5025755637 @default.
• W4328003547 hasAuthorship W4328003547A5026262593 @default.
• W4328003547 hasAuthorship W4328003547A5043858190 @default.
• W4328003547 hasAuthorship W4328003547A5046856172 @default.
• W4328003547 hasAuthorship W4328003547A5047686585 @default.
• W4328003547 hasAuthorship W4328003547A5065243448 @default.
• W4328003547 hasAuthorship W4328003547A5076139079 @default.
• W4328003547 hasBestOaLocation W43280035471 @default.
• W4328003547 hasConcept C121608353 @default.
• W4328003547 hasConcept C126322002 @default.
• W4328003547 hasConcept C143998085 @default.
• W4328003547 hasConcept C187960798 @default.
• W4328003547 hasConcept C207103383 @default.
• W4328003547 hasConcept C2776256026 @default.
• W4328003547 hasConcept C2776478404 @default.
• W4328003547 hasConcept C2776694085 @default.
• W4328003547 hasConcept C2777701055 @default.
• W4328003547 hasConcept C2780030458 @default.
• W4328003547 hasConcept C2781433595 @default.
• W4328003547 hasConcept C44249647 @default.
• W4328003547 hasConcept C71924100 @default.
• W4328003547 hasConcept C95190672 @default.
• W4328003547 hasConceptScore W4328003547C121608353 @default.
• W4328003547 hasConceptScore W4328003547C126322002 @default.
• W4328003547 hasConceptScore W4328003547C143998085 @default.
• W4328003547 hasConceptScore W4328003547C187960798 @default.
• W4328003547 hasConceptScore W4328003547C207103383 @default.

• next